Chinese Innovative Drugs Going Global: RC148 Leads the Charge in Next-Gen Oncology Breakthroughs

As an editor at Hong Kong DengYue Medicine contributing to MolecularCloud, I closely follow the dynamic landscape of global biopharma. In early 2026, one story stands out: RemeGen's RC148, a novel PD-1/VEGF bispecific antibody, secured a landmark exclusive licensing deal with AbbVie. This agreement grants AbbVie rights to develop, manufacture, and commercialize RC148 outside Greater China, with an upfront payment of $650 million and potential milestones up to $4.95 billion—totaling up to $5.6 billion. This isn't just a financial milestone; it's powerful evidence that Chinese-origin innovation is earning trust and accelerating access to cutting-edge therapies worldwide.

For patients battling advanced solid tumors, such as non-small cell lung cancer (NSCLC) or colorectal cancer, these developments bring genuine hope. Many endure multiple lines of treatment only to face progression or resistance. Drugs like RC148 address this by targeting two key pathways simultaneously, offering a more comprehensive attack on cancer while potentially improving outcomes and quality of life.

Spotlight on Leading Chinese Innovations Heading Global

China's biopharma sector continues its remarkable ascent, with out-licensing deals surging and high-value assets drawing international partners. Here are some prominent examples from recent momentum, focusing on mechanisms that tackle unmet needs in oncology and beyond:

• RC148 (RemeGen)Target & Mechanism: Bispecific antibody targeting PD-1 (to restore T-cell anti-tumor activity by blocking immune checkpoint suppression) and VEGF (to inhibit tumor angiogenesis and remodel the immunosuppressive microenvironment). This dual blockade synergizes immunotherapy with anti-vascular effects, potentially overcoming resistance seen in single-target therapies. Indications: Advanced solid tumors, including NSCLC and other malignancies (as monotherapy or in combinations). Clinical Highlights: Early Phase 1/2 studies demonstrate favorable safety and preliminary antitumor activity, with notable responses in combination with antibody-drug conjugates (ADCs). The asset has advanced to Phase 2 in China and received FDA clearance for further trials. Global Impact: The AbbVie partnership accelerates worldwide development, highlighting Chinese bispecifics as competitive next-gen options in crowded oncology spaces.
• Ivonescimab (Akeso)Target & Mechanism: PD-1/VEGF bispecific antibody (pioneering in this class), simultaneously inhibiting PD-1-mediated immune evasion and VEGF-driven vessel formation to enhance immune infiltration and starve tumors. Indications: Advanced NSCLC and other solid tumors. Clinical Highlights: Strong data in head-to-head comparisons against standard PD-1 inhibitors, showing superior progression-free survival in certain settings. Global Impact: Already a benchmark for the PD-1/VEGF class, with ongoing international interest and trials.
• Other Notable Advances Chinese firms are also pushing boundaries in areas like DLL3-targeted ADCs and multi-project platforms, with deals (e.g., historical high-value authorizations) underscoring growing confidence in "Made in China" innovation for global unmet needs.

These examples illustrate how Chinese R&D is shifting from domestic focus to true global contributions, driven by differentiated mechanisms, rigorous clinical validation, and strategic partnerships.

At Hong Kong DengYue Medicine, our core value lies in pursuing excellence and innovation while prioritizing sustainability and social responsibility. We build on quality, compliance, and integrity as foundations—actively engaging in global markets to support outstanding local discoveries in reaching international patients. By fostering collaborations and upholding high standards, we aim to help bridge access gaps and contribute meaningfully to worldwide health improvements.

The journey of Chinese innovative drugs going global is far from over—it's gaining speed and depth. For patients facing cancer or other serious conditions, these stories remind us that breakthroughs can emerge from anywhere, transforming hope into reality through shared scientific progress.

If you're navigating a diagnosis or simply tracking these frontiers, feel free to share thoughts in the MolecularCloud comments. Together, let's stay informed on these life-changing advancements.

(This post is prepared by the Hong Kong DengYue Medicine editorial team for educational purposes only and does not constitute medical advice. Always consult qualified healthcare professionals for personalized guidance.)